Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $53.08M
• Dividend Yield: N/A
• Average Volume (3M): 375.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: -4.22%
• EPS Growth: 18.67%
• Country: US
• Employees: 202
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 37,381,496
• 10 Day Avg. Volume: 531,121
• 30 Day Avg. Volume: 375,599
• PEG Ratio: -0.07
• Price to Book (P/B): -4.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 19.62
• Enterprise Value/Market Cap: 2.70
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 3.16
• Enterprise Value/Ebitda: -0.44
• 1Y Price Target: $10.33
• Price Target Upside: 570.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $1.50 ▼(-2.60%Downside)

Metagenomi, Inc.'s overall stock score reflects strong revenue growth and promising corporate developments in genome editing. However, the score is tempered by ongoing profitability challenges and negative cash flows. Technical indicators suggest stable but cautious market sentiment. Valuation concerns due to negative earnings impact the overall attractiveness for risk-averse investors.

Positive Factors

Collaborations and Partnerships

Metagenomi also leverages several collaborations with Ionis and Affini-T, which could be a good source of continued non-dilutive funds as development advances.

Product Development

Updated data from the Hem A program demonstrate stable FVIII levels, suggesting a strong product profile and providing validation for the secreted protein platform.

Technology Advancements

MGX demonstrated advancements in technology with a system that allows large targeted genome integration in human cells.

Negative Factors

Earnings

MGX reported a Q1 net loss of $25MM and had cash of $226MM.

Financial Performance

MGX reported a net loss per share that was worse than the consensus estimate.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

How the Company Makes Money

Metagenomi, Inc. generates revenue primarily through collaborations and partnerships with pharmaceutical and biotechnology companies. By licensing its proprietary gene editing technologies, Metagenomi earns milestone payments and royalties from the successful development and commercialization of therapeutics based on its innovations. Additionally, the company may engage in research and development agreements, providing expertise and access to its advanced CRISPR systems to partners, contributing further to its revenue streams. Strategic alliances and partnerships play a crucial role in enhancing Metagenomi's financial performance and market reach.

Metagenomi, Inc. Financial Statement Overview

Summary

Metagenomi, Inc. shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is improving with positive equity, but ongoing operational and cash flow challenges need addressing for sustainable growth.

Income Statement

Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.

Balance Sheet

The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.

Cash Flow

Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	45.26M	52.30M	44.76M	17.20M	243.00K
Gross Profit	45.26M	52.30M	-49.65M	15.47M	-144.00K
EBITDA	-82.20M	-83.49M	-74.28M	-39.19M	-20.75M
Net Income	-77.95M	-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet
Total Assets	297.87M	324.60M	364.84M	414.49M	141.99M
Cash, Cash Equivalents and Short-Term Investments	225.97M	248.31M	271.18M	362.13M	108.15M
Total Debt	44.44M	45.78M	48.23M	18.57M	48.93M
Total Liabilities	85.21M	89.74M	500.43M	488.91M	174.54M
Stockholders Equity	212.66M	234.86M	-135.58M	-74.43M	-32.54M
Cash Flow
Free Cash Flow	-104.55M	-112.19M	-101.22M	15.75M	21.35M
Operating Cash Flow	-102.06M	-109.07M	-91.41M	29.72M	24.26M
Investing Cash Flow	31.30M	-88.16M	45.73M	-122.20M	-74.32M
Financing Cash Flow	-2.60M	84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Neutral. The current price of 1.54 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.60, and below the 200-day MA of 2.16, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.76 is Neutral, neither overbought nor oversold. The STOCH value of 48.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	56 Neutral	$5.23B	25.19	-31.27%	5.73%	10.94%	-29.91%
MGX	51 Neutral	$53.08M	―	-31.93%	―	-4.22%	18.67%
DOMH		$79.52M	―	-92.68%	―	―	―
IMAB	45 Neutral	$219.46M	―	-22.38%	―	―	―
IOBT	43 Neutral	$85.65M	―	-138.78%	―	―	32.77%
ADAP	41 Neutral	$62.50M	―	-273.36%	―	883.05%	62.93%
INZY	37 Underperform	$257.60M	―	-141.69%	―	―	-17.06%

Metagenomi, Inc. Corporate Events

Metagenomi, Inc. Holds Annual Stockholders Meeting

On June 10, 2025, Metagenomi, Inc. held its annual meeting of stockholders virtually, where a quorum was established with 18,765,221 shares present or represented by proxy. During the meeting, stockholders elected Willard H. Dere, M.D. as a Class I Director until 2028 and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Metagenomi Showcases Genome Editing Advances at ASGCT 2025

On May 14, 2025, Metagenomi, Inc. announced the presentation of three abstracts at the ASGCT 28th Annual Meeting, showcasing advancements in genome editing technologies. The data highlighted the potential of their compact nucleases for efficient gene editing and the CAST system for precise large gene integration, marking significant progress in developing in vivo precision medicines. These advancements could impact the treatment of neurological disorders and other diseases caused by loss-of-function mutations, enhancing Metagenomi’s position in the gene editing industry.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Metagenomi, Inc. Reports Q1 2025 Financial Results

Metagenomi, Inc. announced its first quarter 2025 financial results and business updates, highlighting a study on Hemophilia A that showed sustained factor VIII activity in nonhuman primates over 19 months, indicating potential for long-term therapeutic effects. The company is well-capitalized with $226 million in cash and securities, expected to support operations into 2027, and continues to advance its AI-driven metagenomics platform, with plans for further studies and technological enhancements.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.